Phase III trial of REGEN-COV in COVID-19 published in NEJM .
The trial met its primary and all secondary endpoints and showed treatment with REGEN-COV significantly reduced the risk of hospitalization or death, with a safety profile consistent with previously reported data. Regeneron previously presented initial results from the Phase III trial at the 2021 American Thoracic Society International Conference (ATS 2021).
In addition, the robust REGEN-COV development program has reported positive Phase III trial results across the spectrum of COVID-19 infection, from prevention to hospitalization: Prevention of symptomatic infection in both uninfected and infected asymptomatic household contacts of SARS-CoV-2 infected individuals. Treatment of non-hospitalized patients already infected with SARS-CoV-2 (as detailed in the publication). Treatment of certain patients hospitalized due to COVID-19 infection, including the RECOVERY trial.
See: "REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19." David M. Weinreich et al. NEJM September 29, 2021 DOI: 10.1056/NEJMoa2108163
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.